Begins Market Coverage on ITMN, BECC, EDXC, and GILD

Follow this company

Companies Mentioned

02/11/2014 [ACCESSWIRE]

Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at to get full access to our free stock reports.

InterMune Inc. (NASDAQ: ITMN) shares closed up 11.29 percent on Monday with over 3.8 million shares traded. The stock has been slowly trending back up since falling when it was revealed on January 31st that the company is suffering from a possible trial data leak from a competitor's idiopathic pulmonary fibrosis drug, which successfully passed its phase 3 trials, and put up solid data.

Get more information on InterMune Inc. and free access to the in-depth equity report at:                                              

Breitling Energy Corporation (OTCBB: BECC) shares closed up 9.09 percent on Monday with about 427,000 shares traded. The stock was one of the biggest gainers in the OTCBB market and hit a new 52-week high of $0.59 during intra-day trading. Earlier this month the company appointed Judson F. Hoover, age 53, as the Company's Chief Financial Officer. Since January 1, 2014, Mr. Hoover has been employed by the Company on an interim basis to provide financial and other services to the Company. Get more information on Breitling Energy Corporation and free access to the in-depth equity report at: ENDEXX Corp. (OTC: EDXC) shares closed up 31.36 percent on Monday with nearly 6 million shares traded. The stock was one of the biggest gainers in the OTC market. There was no news to explain the sudden breakout. ENDEXX Corp., through its subsidiaries, provides platforms for entrepreneurs. It offers m3Hub, a platform that manages patient concentric data and incorporates best patient privacy practices through verification, privacy, legal, and transparent controls, as well as legitimizes the entire transaction process on behalf of patients.

Get more information on ENDEXX Corp. and free access to the in-depth equity report at:                                                                     

Gilead Sciences Inc. (NASDAQ: GILD) shares closed up a modest 2.83 percent on Monday with nearly 10.5 million shares traded. The stock was one of the most active stocks in the NASDAQ. The company announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.

Get more information on Gilead Sciences Inc. and free access to the in-depth equity report at:     


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.



Leave a comment...

Your Name